HER2-POSITIVE BREAST CANCER
Clinical trials for HER2-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for advanced breast cancer: experimental combo enters phase 3 trial
Disease control Not yet recruitingThis phase 3 trial tests a new drug, BL-M07D1, combined with pertuzumab against the standard treatment (docetaxel, trastuzumab, and pertuzumab) in 596 women with HER2-positive breast cancer that has spread or returned. The goal is to see if the new combo delays cancer growth or i…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 16, 2026 23:51 UTC
-
New theranostic approach aims to find and treat brain metastases in one go
Disease control Not yet recruitingThis early-stage trial tests a new type of drug that can both find and treat cancer that has spread to the brain. The study includes 10 adults with solid tumors, specifically HER2-positive breast cancer, that have active brain metastases. The goal is to see if the drug can target…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: MedSIR • Aim: Disease control
Last updated May 16, 2026 23:50 UTC
-
New hope for hard-to-treat breast cancer: experimental drug takes on standard therapy
Disease control Not yet recruitingThis study compares a new drug called SHR-A1811 with a standard combination therapy (pyrotinib plus capecitabine) in 100 people whose HER2-positive advanced breast cancer stopped responding to trastuzumab. The goal is to see which treatment works better at delaying cancer growth.…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated May 16, 2026 23:47 UTC
-
New hope for HER2+ breast cancer patients who stopped responding to previous therapy
Disease control Not yet recruitingThis study tests a new drug combination (RC48 plus chemotherapy) against standard treatment (trastuzumab or inetetamab plus chemo) in people with HER2-positive advanced breast cancer whose disease worsened or who couldn't tolerate a prior type of antibody-drug conjugate. About 26…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2, PHASE3 • Sponsor: Fudan University • Aim: Disease control
Last updated May 16, 2026 23:46 UTC
-
New hope for advanced breast cancer: maintenance therapy trial launches
Disease control Not yet recruitingThis study tests whether a combination of targeted drugs and hormone therapy can keep advanced HER2-positive breast cancer under control after an initial powerful treatment. About 288 women with cancer that has spread or cannot be removed will receive different maintenance therap…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New triple combo aims to hold back advanced breast cancer
Disease control Not yet recruitingThis study looks at whether adding pyrotinib to two standard drugs (trastuzumab and pertuzumab) can help keep HER2-positive advanced breast cancer from growing longer. About 42 adults with advanced or recurrent HER2-positive breast cancer will receive this combination as maintena…
Matched conditions: HER2-POSITIVE BREAST CANCER
Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New hope for breast cancer patients with brain tumors: drug combo enters trial
Disease control Not yet recruitingThis phase 2 trial tests whether adding neratinib to the standard drug trastuzumab deruxtecan helps control HER2-positive breast cancer that has spread to the brain. About 202 women aged 18-70 will be randomly assigned to one of two treatment groups. The goal is to see if the com…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
Could breast cancer treatment skip surgery? new trial explores non-surgical path
Disease control Not yet recruitingThis study tests whether some people with early-stage breast cancer can safely avoid surgery after chemotherapy and radiation. Participants will be monitored with MRIs, mammograms, and blood tests to check if the cancer stays away. The goal is to see if a non-surgical approach wo…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
New combo therapy targets breast cancer brain tumors
Disease control Not yet recruitingThis early-phase study tests a targeted drug (trastuzumab deruxtecan) combined with precise radiation (stereotactic radiosurgery) in 20 people with HER2-positive breast cancer that has spread to the brain. The goal is to find the safest drug dose and see how well the combination …
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New pill aims to stop dangerous platelet drop in breast cancer treatment
Prevention Not yet recruitingThis study tests whether herombopag olamine tablets can prevent low platelet counts in people with HER2-positive breast cancer receiving T-DM1 therapy. Low platelets are common in Asian patients and can cause bleeding or force treatment delays. The trial will enroll 45 participan…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: NA • Sponsor: Zhenzhen Liu • Aim: Prevention
Last updated May 14, 2026 12:05 UTC